A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. - Wikidata - awgldk - TriplyDB

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

http://www.wikidata.org/entity/Q35591553

about

Ivacaftor for patients with cystic fibrosis Update in Cystic Fibrosis 2014 Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences New and emerging targeted therapies for cystic fibrosis Key mechanisms governing resolution of lung inflammation Computed tomography dose optimisation in cystic fibrosis: A review Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis Advancing clinical development pathways for new CFTR modulators in cystic fibrosis Allergen Immunotherapy (AIT): a prototype of Precision Medicine Targeted therapies to improve CFTR function in cystic fibrosis Inhaled therapy in cystic fibrosis: agents, devices and regimens Testing cardiovascular drug safety and efficacy in randomized trials Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment The Evolution of Cystic Fibrosis Care Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung Open-access biorepository for idiopathic pulmonary fibrosis. The way forward The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities Cystic fibrosis therapeutics: the road ahead Early pulmonary inflammation and lung damage in children with cystic fibrosis Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms Origins of cystic fibrosis lung disease A functional CFTR assay using primary cystic fibrosis intestinal organoids Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines Paediatrics: messages from Munich Recent new drug approvals. Part 1: drugs with pediatric indications A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease Barriers to inhaled gene therapy of obstructive lung diseases: A review Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Background and Epidemiology The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability Development of CFTR Structure Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age?Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.

P2860

Q22305938-4FD9DD12-1439-45EA-92F1-4B0EC58C4BC5 Q22306307-8F5965C9-7880-4207-9272-E65AE7FE5EBA Q24187139-E6D5BD1E-21C2-4727-B90E-811249CB7391 Q26747065-21B22CDE-8EB3-49ED-954B-D5D7F683D3EA Q26747210-28465D6A-2E6C-433E-9AAF-40160870B21E Q26749278-48E3E1AB-7D8A-4F78-A592-A233B31596D6 Q26749606-0D1F5F23-EF75-47AC-BD60-664454A756F2 Q26751283-3E0D1D6A-6AF9-49D9-B73C-F6923FF484F0 Q26765794-301BFE09-39B1-4350-82EF-D8386767EF4A Q26768266-7D46DA6F-2D40-4AF4-A343-C6A1EE848A93 Q26776512-8EBA80F0-0839-44AB-81A9-7DA81BDD6298 Q26781441-6E2293DC-AA16-4627-AC99-734BF301734D Q26797450-10D1751C-54FF-4BA6-BDBB-974711C88658 Q26849771-5487CC73-E610-4ADB-B211-43BE7F7E0A87 Q26851242-31B0D8B3-FF5D-418C-B245-2FDD82EC4BBB Q26999299-389085C8-B349-420B-872B-0BE7C5915BD9 Q27001070-3DC03A32-0B85-496F-BB41-D2C9A26F029A Q27003322-576FEDAD-80AA-4CFE-9AC4-90AC2DBEE63C Q27014740-39937F71-5263-48D1-8E6D-C3331FEADD53 Q27022401-DFBAF0F2-6A48-4705-9D71-0DAE184B6565 Q27027040-5CAE9A51-CFDE-434C-BA8D-DC8C53E41A4D Q28073063-C5222CE0-2302-47C1-92B5-558AAB39E407 Q28073996-0DBA2E90-D5C3-40E3-A259-24BA1329B653 Q28077411-791E8A31-2E8C-4336-AF89-61B6369E3D75 Q28080451-411BD72C-E382-4A54-A775-B27E6333CC63 Q28291898-CB5741B2-689A-4F6D-986B-BD916289C19C Q28550065-16E20432-A868-416B-8B95-199A10101F3E Q28596759-6EA4AB40-1366-4B5F-BD43-FF31386C0DBD Q28709081-0D7BBBD2-5F75-45F5-A6D4-BDB9A3E45A49 Q28727685-778F8854-FDDF-4C0D-BDDC-9D43464EC1FC Q29248141-5FFAEC47-A5E3-4A6C-9EBC-071C06F467D4 Q30238814-C5F16C74-74A1-45F3-A883-ECE23DAA1438 Q30248742-F0FD764B-4D44-4457-8C5D-E25B0E1EDD7A Q30394029-897D6D74-05D5-4F25-868B-B67937F4D061 Q30421217-B577C03C-CD47-4968-9C3C-BF4ED341209D Q30487537-6280FD17-C883-4C6F-B13E-79AD9A146CD2 Q30574556-41EA8869-5D51-41BB-9810-388A07C5750E Q30784080-DC6C1F25-82F4-4B69-8DB4-99E5D295052F Q30978102-205C6070-8D50-443A-9FFB-0DF558A3623E Q31017820-7CC2F94A-965D-4E94-A2AD-52E6277F474A

P2860

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

http://www.wikidata.org/entity/Q35591553

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@ast

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@en

type

label

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@ast

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@en

prefLabel

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@ast

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@en

P1433

Q35591553-23E67207-A629-4107-8E30-905A7418F329

P1476

Q35591553-6738C83B-5F3E-4599-82DB-0C6FEC7BF945

P2093

Q35591553-123DEBE2-3B77-4DD4-8EA2-397129B9511D

Q35591553-21AA59ED-D31F-4553-AC63-A268918356FF

Q35591553-2409DA54-1F15-4984-8133-E9CE672902F1

Q35591553-3B5107EC-08B2-4FAE-B2AA-2D9B758E3108

Q35591553-5C158E23-3026-46E1-AF43-408FFBD74078

Q35591553-629E971E-5E05-4C58-9218-712B9B952CC5

Q35591553-76D42079-57F9-41C1-AB3E-47FFFDDC5327

Q35591553-7E09787A-F2EE-4595-99E8-A32F2A0F6A86

Q35591553-97BBFF40-23A2-46D6-B38F-1061B32CFFEE

Q35591553-CF83113F-AA60-4979-B6ED-CA93BE5B581E

P2860

Q35591553-042E867C-4A70-49FF-88D6-0806D997C159

Q35591553-05B5674F-241A-4744-B32C-48C9F97B9119

Q35591553-09571052-9E31-41BF-9ED1-9BF0B174A78C

Q35591553-0BEBD5B2-D686-4B79-98C6-F2E413219A2C

Q35591553-28C2804B-78CA-47D3-B174-6839659A7F90

Q35591553-314BB082-1CDD-4F2E-B2BD-15F483B43109

Q35591553-37C28230-BAF5-4009-8E17-C892FF33C7AE

Q35591553-40B7BC24-DFED-400E-93EE-7DDE901060B8

Q35591553-4DA247D5-FFBD-4CA2-BA57-E25C2237536A

Q35591553-6EA76251-979B-427C-8114-7273C833E5DC

P304

Q35591553-7B6EECB6-32F4-44BB-BC12-3A8D9D1CBCE8

P31

Q35591553-ABE98430-00E7-4C6B-A304-4AA910CCB5F2

P356

Q35591553-C5A71AA5-F547-42B7-9265-E97615C076C6

P407

Q35591553-40C93F19-BB90-4BF2-92EB-D0CB1B8B5983

P433

Q35591553-0C358D82-CC4F-4473-AD75-FA9805AD573B

P478

Q35591553-DD65BB73-5B58-47C9-BD3D-040BDEE55EBB

P50

Q35591553-111E9633-1697-4206-AD15-603741DF584E

Q35591553-1EC8D4E4-56A7-441F-92D2-DCC9414BBF20

Q35591553-3C8E010B-20CD-46A1-B8D8-5AC2C261FE79

Q35591553-C19C755D-ADAE-4222-996E-43CE98291390

P577

Q35591553-4806CB0E-AA02-43E8-AD2F-2652A1D5402D

P5875

Q35591553-A4F8344F-083B-4B77-AA18-DF1107A735EE

P698

Q35591553-676535B5-501E-47CD-84D9-C187FC5B78CC

P921

Q35591553-3EA91C3A-336C-4676-B9C1-A2A32BEBF64B

Q35591553-487E5A64-604F-471C-8527-F798FBF8F083

Q35591553-AC6E49D6-862B-4D94-86F2-0340A36B6C74

P932

Q35591553-C8B986E5-21C3-44AF-B6F2-D81CAAF7935A

P356

P1433

The New England Journal of Medicine

P1476

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

@en

P2093

Bonnie W Ramsey

http://www.w3.org/2001/XMLSchema#string

Claudia Ordoñez

http://www.w3.org/2001/XMLSchema#string

Edward F McKone

http://www.w3.org/2001/XMLSchema#string

Elizabeth Tullis

http://www.w3.org/2001/XMLSchema#string

Isabelle Sermet-Gaudelus

http://www.w3.org/2001/XMLSchema#string

Jane Davies

http://www.w3.org/2001/XMLSchema#string

Karl Yen

http://www.w3.org/2001/XMLSchema#string

Matthias Griese

http://www.w3.org/2001/XMLSchema#string

Michael W Konstan

http://www.w3.org/2001/XMLSchema#string

N Gerard McElvaney

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Cystic fibrosis

Identification of the cystic fibrosis gene: genetic analysis

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.

Changes in the normal maximal expiratory flow-volume curve with growth and aging.

P304

1663-1672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1105185

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Claire Wainwright

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51764596

http://www.w3.org/2001/XMLSchema#string

P698

22047557

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

3230303

http://www.w3.org/2001/XMLSchema#string